Last reviewed · How we verify
Bromofluorescein (eosin)
Bromofluorescein (generic name: eosin) is a eosin drug. It is currently in unknown development.
Bromofluorescein (eosin) works by binding to and inhibiting the activity of Protein arginine N-methyltransferase 1.
Bromofluorescein is a small molecule with various synonyms, including ACID RED 87 and C.I. 45380. It is used to stain proteins, collagen, and muscle fibers, causing them to appear dark red or pink due to its binding properties.
At a glance
| Generic name | eosin |
|---|---|
| Drug class | eosin |
| Target | Protein arginine N-methyltransferase 1, RmtA |
| Therapeutic area | Other |
| Phase | unknown |
Mechanism of action
Think of it like a key fitting into a lock. Bromofluorescein (eosin) is the key that blocks the lock, preventing Protein arginine N-methyltransferase 1 from doing its job. This can help to slow down or stop the progression of certain diseases.
Approved indications
Common side effects
Key clinical trials
- Comparison Between Liquid-Based Cytology And Molecular Screening For Detecting Precursor Lesions and Cervical Cancer (NA)
- Comparison Of Cytology And Molecular Screening For Detecting Cervical Reactive Cellular Changes In General Population (NA)
- Multi-modal Fusion Model and Deep Learning for Predicting Treatment Response in NKTCL
- Effect of Injectable Hyaluronic Acid (HYADENT BG (HA)) on Bone Healing in Extraction Sockets (NA)
- Dynamic Multi-omics Integration Model to Predict Neoadjuvant Therapy Response in Locally Advanced Rectal Cancer
- Carbon Suspension vs. Metallic Marker for Axillary Lymph Node Marking in Breast Cancer After Neoadjuvant Therapy (NA)
- Effect of Vitamin C on Collagen Production in Comparison to Hereditary Gingival Fibromatosis: Histopathological Study (NA)
- Precision Recurrence Risk Assessment in Early-stage Hepatocellular Carcinoma
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bromofluorescein CI brief — competitive landscape report
- Bromofluorescein updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Bromofluorescein
What is Bromofluorescein?
How does Bromofluorescein work?
What is the generic name of Bromofluorescein?
What drug class is Bromofluorescein in?
What development phase is Bromofluorescein in?
What does Bromofluorescein target?
Related
- Drug class: All eosin drugs
- Target: All drugs targeting Protein arginine N-methyltransferase 1, RmtA
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing